Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK5 | P34947 | 11/20 | 0.52 |
| ▸ | MET | P08581 | 13/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | GRK2 | P25098 | 6/20 | 0.51 |
| ▸ | FLT3 | P36888 | 3/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | MST1R | Q04912 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2749684 | 0.94 | GRK5 (0.54) | GRK5METKCNH2GRK2FLT3 | |
| SCHEMBL2749144 | 0.89 | GRK5 (0.61) | GRK5METKCNH2GRK2FLT3 | |
| SCHEMBL2750834 | 0.88 | MAP4K3 (0.57) | GRK5METKCNH2GRK2FLT3 | |
| SCHEMBL2748605 | 0.87 | GRK5 (0.57) | GRK5METKCNH2GRK2FLT3 | |
| SCHEMBL2748093 | 0.86 | GRK5 (0.47) | GRK5METKCNH2GRK2FLT3 | |
| SCHEMBL2749292 | 0.85 | MET (0.56) | GRK5METKCNH2GRK2FLT3 | |
| SCHEMBL2749754 | 0.85 | MET (0.56) | GRK5METKCNH2GRK2FLT3 | |
| SCHEMBL2748703 | 0.85 | MET (0.67) | GRK5METKCNH2GRK2FLT3 | |
| SCHEMBL2385920 | 0.84 | MET (0.66) | GRK5METKCNH2GRK2FLT3 | |
| SCHEMBL2749263 | 0.83 | GRK5 (0.54) | GRK5METKCNH2GRK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | GRK5 317/4885MET 38/4885KCNH2 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.